Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone312-819-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.47 billion
Profitability
Miscellaneous
Employees10,000
Next Earnings Date11/1/2019 (Confirmed)
OptionableOptionable
Hill-Rom (NYSE:HRC) Frequently Asked Questions
What is Hill-Rom's stock symbol?
Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."
How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom?
Hill-Rom declared a quarterly dividend on Tuesday, July 16th. Investors of record on Friday, September 20th will be paid a dividend of $0.21 per share on Monday, September 30th. This represents a $0.84 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date is Thursday, September 19th. View Hill-Rom's Dividend History.
How were Hill-Rom's earnings last quarter?
Hill-Rom Holdings, Inc. (NYSE:HRC) issued its quarterly earnings data on Friday, August, 2nd. The medical technology company reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $1.21 by $0.02. The medical technology company earned $726.80 million during the quarter, compared to the consensus estimate of $718.08 million. Hill-Rom had a net margin of 7.45% and a return on equity of 21.26%. The firm's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.15 EPS. View Hill-Rom's Earnings History.
When is Hill-Rom's next earnings date?
How can I listen to Hill-Rom's earnings call?
Hill-Rom will be holding an earnings conference call on Friday, November 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Hill-Rom issued on next quarter's earnings?
Hill-Rom issued an update on its fourth quarter earnings guidance on Friday, August, 2nd. The company provided EPS guidance of $1.64-1.66 for the period, compared to the Thomson Reuters consensus estimate of $1.67.
What price target have analysts set for HRC?
6 analysts have issued 12 month price targets for Hill-Rom's shares. Their predictions range from $98.00 to $125.00. On average, they anticipate Hill-Rom's stock price to reach $114.00 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Price Targets for Hill-Rom.
What is the consensus analysts' recommendation for Hill-Rom?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hill-Rom.
What are Wall Street analysts saying about Hill-Rom stock?
Here are some recent quotes from research analysts about Hill-Rom stock:
- 1. According to Zacks Investment Research, "Hill-Rom exited the second quarter of fiscal 2019 on a strong note with better-than-expected numbers. The company saw a solid year-over-year increase in domestic revenues, driven by sturdy performance in Patient Support Systems and Front Line Care. We are upbeat to note the company’s strong momentum across its diversified product portfolio which includes Centrella Smart+ bed, Welch AllynConnex Spot Monitor, Monarch Airway Clearance System, Integrated Table Motion for the da Vinci Xi Surgical System. The acquisition of Voalte buoys optimism as it boosts Hill-Rom’s digital and mobile communications platform. Overall, Hill-Rom has outperformed its industry in the past six months. However, foreign exchange and a tough competitive landscape remain headwinds. Also, Hill-Rom’s global revenue growth was sluggish in the quarter." (6/6/2019)
- 2. Needham & Company LLC analysts commented, "HRC announced that it has entered into a definitive agreement to acquire Voalte (private) for $180M up front and up to $15M in commercial-based milestones. HRC believes it can absorb the dilutive impact of the deal in FY19, expects the transaction to close in F3Q19, and estimates the deal to become increasingly accretive beginning in FY20. Voalte offers smartphone and web-based applications that enable caregivers to communicate securely and provides managers data analytics tools, respectively. The Voalte deal seems to make financial (accretive to revenue growth and margins) and strategic (further diversifies HRC away from capital equipment sales and allows for cross-selling opportunities in its care communications business) sense, in our view, and we reiterate our Buy rating." (3/11/2019)
Has Hill-Rom been receiving favorable news coverage?
News headlines about HRC stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hill-Rom earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the medical technology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Hill-Rom.
Who are some of Hill-Rom's key competitors?
Some companies that are related to Hill-Rom include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Cantel Medical (CMD).
What other stocks do shareholders of Hill-Rom own?
Who are Hill-Rom's key executives?
Hill-Rom's management team includes the folowing people:
- Mr. John P. Groetelaars, Pres, CEO & Director (Age 52)
- Mr. Carlos Alonso-Marum, Sr. VP & Pres of International (Age 60)
- Mr. Paul Johnson, Sr. VP & Pres of Patient Support Systems (Age 54)
- Mr. Steven J. Strobel, Sr. Advisor (Age 61)
- Ms. Barbara W. Bodem, Sr. VP & CFO (Age 51)
Who are Hill-Rom's major shareholders?
Hill-Rom's stock is owned by many different of retail and institutional investors. Top institutional investors include Mountain Pacific Investment Advisers Inc. ID (0.30%), Copper Rock Capital Partners LLC (0.20%), Valeo Financial Advisors LLC (0.13%), Envestnet Asset Management Inc. (0.10%), CHURCHILL MANAGEMENT Corp (0.08%) and Three Peaks Capital Management LLC (0.08%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Deborah Rasin, John J Greisch, Mary Garrett and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.
Which major investors are selling Hill-Rom stock?
HRC stock was sold by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Fox Run Management L.L.C., Brookstone Capital Management, Pacer Advisors Inc., Oakbrook Investments LLC, Valeo Financial Advisors LLC, NEXT Financial Group Inc and Campbell & CO Investment Adviser LLC. Company insiders that have sold Hill-Rom company stock in the last year include Andreas G Frank, Deborah Rasin and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.
Which major investors are buying Hill-Rom stock?
HRC stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., State of Alaska Department of Revenue, CHURCHILL MANAGEMENT Corp, Nisa Investment Advisors LLC, Courier Capital LLC, Meeder Asset Management Inc., Three Peaks Capital Management LLC and Cerebellum GP LLC. View Insider Buying and Selling for Hill-Rom.
How do I buy shares of Hill-Rom?
Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Hill-Rom's stock price today?
One share of HRC stock can currently be purchased for approximately $102.03.
How big of a company is Hill-Rom?
Hill-Rom has a market capitalization of $6.82 billion and generates $2.47 billion in revenue each year. The medical technology company earns $252.40 million in net income (profit) each year or $4.75 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.View Additional Information About Hill-Rom.
What is Hill-Rom's official website?
How can I contact Hill-Rom?
Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]
MarketBeat Community Rating for Hill-Rom (NYSE HRC)
MarketBeat's community ratings are surveys of what our community members think about Hill-Rom and other stocks. Vote "Outperform" if you believe HRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
